Superiority of R-CHOP to CHOP was also observed in the MInT Trial (MabThera International Trial) that randomized 823 patients 18 to 60 year-old with favorable (IPI 0-1), stage II-IV DLBCL (or bulky stage I) to 6 cycles of R-CHOP versus 6 cycles of CHOP (5). This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.